Search
for
Sort by
Research 30 of 1000+
- Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?
- Post-SSRI sexual dysfunction & other enduring sexual dysfunctions
- Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants
- POST-FINASTERIDE SYNDROME AND POST-SSRI SEXUAL DYSFUNCTION: TWO CLINICAL CONDITIONS APPARENTLY DISTANT, BUT VERY CLOSE
- Insights into the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI and post-accutane syndromes: lessons learned from a case study
- Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin
- Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.
- Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.
- Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
- Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
- Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
- PSSD,PFS,PRSD: A perspective for aetiology and treatment
- Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
- Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
- The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations
- O "25 de Abril" como ruptura sociobiográfica: potenciaçoes e refracçoes no campo cultural
- Persistent adverse effects of antidepressants
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Post-finasteride syndrome
- Treatment of female sexual dysfunction in postmenopausal women—What is the evidence?
- Androgens and Female Sexual Function and Dysfunction—Findings From the Fourth International Consultation of Sexual Medicine
- REPORTS: Summary of the Recommendations on Sexual Dysfunctions in Women
- Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Post-finasteride syndrome: An emerging clinical problem
- Post-finasteride syndrome – does it really exist?
- The pathophysiology of delayed ejaculation
- Neurosteroids, neuroactive steroids, and symptoms of affective disorders
- Commonly encountered symptoms and their management in patients with cirrhosis